Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2 -yl)-piperidine-2,6-dione for treatment of certain leukemias

Details for Australian Patent Application No. 2006299431 (hide)

Owner Celgene Corporation

Inventors Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2006299431

PCT Pub. Number WO2007/041637

Priority 11/244,117 04.10.05 US

Filing date 3 October 2006

Wipo publication date 12 April 2007

Acceptance publication date 10 November 2011

International Classifications

A61K 31/00 (2006.01)

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/425 (2006.01) - Thiazoles

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/454 (2006.01)

A61K 31/515 (2006.01)

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/02 (2006.01) Antineoplastic agents

C07H 19/20 (2006.01) Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical

Event Publications

17 April 2008 PCT application entered the National Phase

  PCT publication WO2007/041637 Priority application(s): WO2007/041637

10 November 2011 Application Accepted

  Published as AU-B-2006299431

8 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006299436-Externally-applied patient interface system and method

2006299429-Fc variants with optimized Fc receptor binding properties